Xenon - NeuroproteXenon

Drug Profile

Xenon - NeuroproteXenon

Alternative Names: XENEX

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroproteXeon
  • Class Elements; General anaesthetics
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic brain damage
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic brain damage

Most Recent Events

  • 09 May 2018 NeuroproteXeon and Linde enter into distribution agreement for xenon inhalation in European Union, Switzerland, Norway and Iceland for Brain damage (in post cardiac arrest syndrome)
  • 02 Oct 2017 Mallinckrodt and NeuroproteXeon agree to co-promote and co-develop Xenon for Neuroprotection in Australia, Canada, Japan and USA
  • 02 Oct 2017 Updated efficacy data from a phase II trial in Brain damage (Combination therapy) released by NeuroproteXeon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top